Want to see HK:0575 full AI Analyst Report?
Top Page
Endurance RP
(0575)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.79
▼(-17.37% Downside)
Action:Reiterated
Date:09/18/26
The score is primarily weighed down by weak financial performance (ongoing losses, revenue volatility, persistent cash burn, and negative equity). Technicals are neutral rather than supportive (negative MACD with only moderate RSI), and valuation is constrained by a negative P/E with no dividend yield data to offset the risk.
Positive Factors
High 2025 gross margin
The very high 2025 gross margin indicates that the company can retain substantial value from reported sales before operating costs. If maintained and paired with better expense control, this could provide operating leverage and support a path toward improved profitability, although the historical inconsistency limits confidence.
Negative Factors
Deepening losses
Deteriorating net margins and materially negative EBIT and EBITDA show that the business is not converting revenue into operating or bottom-line profit. Persistent losses can consume capital, restrict reinvestment capacity, and make any recovery dependent on substantial operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
High 2025 gross margin
The very high 2025 gross margin indicates that the company can retain substantial value from reported sales before operating costs. If maintained and paired with better expense control, this could provide operating leverage and support a path toward improved profitability, although the historical inconsistency limits confidence.
Read all positive factors
Endurance RP (0575) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$253.88M
Dividend Yield87.25%
Average Volume (3M)69.98K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth489.92%
EPS Growth62.36%
CountryHK
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding291,815,800
10 Day Avg. Volume67,993
30 Day Avg. Volume69,977
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)-5.41
Price to Sales (P/S)98.99
P/FCF Ratio-8.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Endurance RP Business Overview & Revenue Model
Company Description
Regent Pacific Group Limited is an investment holding company that primarily focuses on the healthcare and life sciences sectors. The company is involved in the research, development, and sale of pharmaceutical products, with a notable focus on tr...
Endurance RP Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
11
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.42M | 363.00K | 719.00K | 382.00K | 114.00K | 3.25M |
| Gross Profit | 5.02M | -420.00K | -219.00K | -2.34M | -1.11M | 850.00K |
| EBITDA | -896.32K | -4.29M | -4.18M | -7.72M | -9.56M | 10.38M |
| Net Income | -1.95M | -4.71M | -4.48M | -25.05M | -36.43M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 5.73M | 570.92K | 610.00K | 2.79M | 26.32M | 62.23M |
| Cash, Cash Equivalents and Short-Term Investments | 255.96K | 187.97K | 121.00K | 2.42M | 1.41M | 11.13M |
| Total Debt | 7.36M | 3.94M | 3.34M | 1.20M | 13.73M | 14.01M |
| Total Liabilities | 11.78M | 7.21M | 6.51M | 4.35M | 23.72M | 23.46M |
| Stockholders Equity | -6.05M | -6.64M | -5.90M | -1.55M | 2.60M | 38.77M |
Cash Flow | ||||||
| Free Cash Flow | -4.53M | -4.32M | -4.13M | -3.59M | 533.00K | -1.75M |
| Operating Cash Flow | -4.52M | -4.30M | -4.13M | -3.59M | 545.00K | -1.70M |
| Investing Cash Flow | -7.00K | -15.02K | -3.00K | -1.00K | -7.00K | 123.00K |
| Financing Cash Flow | 4.56M | 4.35M | 2.14M | 5.58M | -795.00K | -782.00K |
Endurance RP Technical Analysis
Neutral
0.95
Price Trends
0.85
Positive
0.87
Negative
0.85
Positive
Market Momentum
<0.01
Negative
50.22
Neutral
61.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0575, the sentiment is Neutral. The current price of 0.95 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.85, and above the 200-day MA of 0.85, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.22 is Neutral, neither overbought nor oversold. The STOCH value of 61.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0575.
Endurance RP Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$128.02M | -4.55 | -4.90% | ― | -126.01% | -237.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$84.47M | -6.60 | -82.36% | 13.54% | ― | 79.32% | |
46 Neutral | HK$225.88M | -0.12 | -16.70% | 2.91% | 163.09% | 52.42% | |
45 Neutral | HK$253.88M | -16.55 | 30.76% | 87.25% | 489.92% | 62.36% | |
43 Neutral | HK$613.36M | -16.65 | -13.47% | 1.45% | 40.35% | -327.36% | |
43 Neutral | HK$291.60M | -39.94 | -66.95% | ― | ― | -700.00% |
* Healthcare Sector Average
HK:0575
Endurance RP
0.87
0.21
31.82%
HK:0129
Asia Standard International Group
0.16
-0.14
-47.00%
HK:1217
China Innovation Investment Limited
0.01
>-0.01
-28.57%
HK:1835
Shanghai Realway Capital Assets Management Co., Ltd. Class H
4.00
1.98
98.02%
HK:0310
Prosperity Investment Holdings Limited
0.14
-0.09
-40.35%
HK:0339
Core Economy Investment Group Limited
0.68
0.51
299.41%
Endurance RP Corporate Events
Regent Pacific’s Deep Longevity to Launch Accrua Telehealth Platform Across U.S.
Sep 28, 2026
Regent Pacific’s Deep Longevity unit will launch Accrua, a consumer digital health and telehealth platform, across all 50 U.S. states in October 2026, marking its first large-scale direct-to-consumer push. The service combines online clinici...
Regent Pacific Secures Milestone Payment as Fosun Readies Senstend Launch in China
Sep 1, 2026
Regent Pacific Group has received a US$4.5 million milestone payment from Fosun Wanbang (Jiangsu) Pharmaceutical Group under their licensing and collaboration agreement for Senstend™ in mainland China, reinforcing the strength of their strat...
Endurance RP lifts profit on China milestone as telehealth and Fortacin™ expansion advance
Aug 25, 2026
Endurance RP reported an unaudited profit of about US$544,000 for the six months to 30 June 2026, driven primarily by a US$5 million milestone from Fosun Wanbang following Chinese approval of Senstend™, partially offset by impairment charges...
Regent Pacific Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 13, 2026
Regent Pacific Group Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their release to the market. The board will also consider whether to declare ...
Regent Pacific Signals Return to Profit on Senstend Milestone Payment
Aug 3, 2026
Regent Pacific Group Limited has issued a positive profit alert, indicating it expects to post a net profit of between US$0.5 million and US$1 million for the six months ended 30 June 2026, versus a loss of about US$2.22 million a year earlier. Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.